Positive News Sentiment NASDAQ:TCRX TScan Therapeutics - TCRX News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.35 +0.03 (+1.29%) (As of 03/27/2023 02:29 PM ET) Add Compare Share Share Today's Range$2.30▼$2.3950-Day Range$1.73▼$3.3252-Week Range$1.45▼$4.56Volume12,908 shsAverage Volume167,577 shsMarket Capitalization$56.94 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Media Mentions By Week TCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼1.870.71▲Average Medical News Sentiment TCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼10▲TCRX Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTScan Therapeutics Shares Rise 8% After First Patient Dosed With TSC-101marketwatch.com - March 15 at 12:55 PMTScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignanciesfinance.yahoo.com - March 14 at 8:14 AMTScan Therapeutics to Participate in the Barclays Global Healthcare Conferencefinance.yahoo.com - March 13 at 4:51 PMTScan Therapeutics's Return On Capital Employed Insightsmsn.com - March 10 at 6:08 PMTScan Therapeutics Full Year 2022 Earnings: Misses Expectationsfinance.yahoo.com - March 10 at 8:51 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and TScan Therapeutics (TCRX)markets.businessinsider.com - March 9 at 6:56 AMH.C. Wainwright Keeps Their Buy Rating on TScan Therapeutics (TCRX)markets.businessinsider.com - March 9 at 6:56 AMTScan Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $3.09M misses by $1.01Mmsn.com - March 8 at 10:55 AMTScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestonesfinance.yahoo.com - March 8 at 10:55 AMTScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conferencefinance.yahoo.com - March 1 at 8:19 AMTScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conferencefinance.yahoo.com - February 21 at 11:48 AMTScan Announces FDA Clearance Of 3 INDs For Solid Tumorsmarkets.businessinsider.com - January 23 at 9:36 AMTScan stock rises ~15% on FDA nod to start trials of cancer drugsmsn.com - January 23 at 9:36 AMTScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumorsfinance.yahoo.com - January 23 at 9:36 AMTScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progressfinance.yahoo.com - January 5 at 9:22 AMTScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022finance.yahoo.com - December 12 at 7:18 AMA number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholdersfinance.yahoo.com - December 9 at 10:55 AMTScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globefinance.yahoo.com - December 1 at 2:42 PMTScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conferencefinance.yahoo.com - November 22 at 11:56 AMTScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meetingfinance.yahoo.com - November 11 at 10:21 AMTScan Therapeutics, Inc.: TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatefinanznachrichten.de - November 9 at 9:20 AMTScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - November 9 at 9:20 AMTScan Therapeutics Announces Upcoming Virtual Investor Eventfinance.yahoo.com - November 7 at 10:25 AMTScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Expositionfinance.yahoo.com - November 3 at 10:53 AMTScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meetingfinance.yahoo.com - October 5 at 10:12 AMTScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVenturesfinance.yahoo.com - September 12 at 10:53 AMTScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conferencefinance.yahoo.com - September 7 at 7:53 AMTScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimatesfinance.yahoo.com - August 13 at 12:52 PMNew Forecasts: Here's What Analysts Think The Future Holds For TScan Therapeutics, Inc. (NASDAQ:TCRX)finance.yahoo.com - August 12 at 10:43 AMTScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progressfinance.yahoo.com - August 10 at 12:19 PMShareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year agofinance.yahoo.com - August 5 at 1:10 PMTScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conferencefinance.yahoo.com - August 3 at 8:36 AMTScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technologyfinance.yahoo.com - July 11 at 8:56 AMTScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officerfinance.yahoo.com - July 7 at 9:58 AMIs TScan Therapeutics (NASDAQ:TCRX) In A Good Position To Invest In Growth?finance.yahoo.com - July 6 at 6:47 PMTScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposiumfinance.yahoo.com - June 22 at 8:37 AMTScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 8:30 AMTScan gets FDA nod to start trial of TSC-101 in blood cancer patients undergoing cell transplantseekingalpha.com - May 31 at 11:11 AMInsider Buying: The TScan Therapeutics, Inc. (NASDAQ:TCRX) President Just Bought 17% More Sharesfinance.yahoo.com - May 22 at 11:32 AMTScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meetingfinance.yahoo.com - May 19 at 8:50 AMTScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - May 17 at 8:36 AMTScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meetingfinance.yahoo.com - May 12 at 8:39 AMTScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestonesfinance.yahoo.com - May 9 at 11:42 AMTScan Therapeutics, Inc.'s (NASDAQ:TCRX) recent US$6.0m market cap decline means a loss of US$233k for insiders who bought this yearfinance.yahoo.com - May 5 at 3:26 PMTScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meetingfinance.yahoo.com - May 2 at 5:24 PMTScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Financefinance.yahoo.com - April 11 at 8:53 AMDo Institutions Own TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares?finance.yahoo.com - February 18 at 5:32 PMTScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conferencefinance.yahoo.com - February 10 at 6:55 PMFDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignanciesfinance.yahoo.com - January 24 at 4:26 PMTScan gets FDA nod to start clinical studies for TSC-100 in leukemia patientsseekingalpha.com - January 24 at 9:31 AM Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:TCRX) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.